Aratana Therapeutics Inc  

(Public, NASDAQ:PETX)   Watch this stock  
Find more results for Wendy L. Yarno
6.45
-0.07 (-1.07%)
After Hours: 6.45 0.00 (0.00%)
Jul 25, 4:31PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.35 - 6.57
52 week 2.56 - 19.99
Open 6.54
Vol / Avg. 0.00/431,760.00
Mkt cap 226.25M
P/E     -
Div/yield     -
EPS -2.71
Shares 35.35M
Beta 3.78
Inst. own 92%
Aug 5, 2016
Q2 2016 Aratana Therapeutics Inc Earnings Call - 8:30AM EDT - Add to calendar
Aug 4, 2016
Q2 2016 Aratana Therapeutics Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 24, 2016
Aratana Therapeutics Inc Annual Shareholders Meeting
Jun 17, 2016
Aratana Therapeutics Inc Annual Shareholders Meeting (Estimated)
Jun 7, 2016
Aratana Therapeutics Inc at Jefferies Healthcare Conference
Jun 1, 2016
Aratana Therapeutics Inc at Stifel Dental & Veterinary Conference
May 10, 2016
Aratana Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2016
Q1 2016 Aratana Therapeutics Inc Earnings Call
May 5, 2016
Q1 2016 Aratana Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -10504.07% -12397.34%
Operating margin -10034.88% -13200.00%
EBITD margin - -6527.73%
Return on average assets -51.20% -47.36%
Return on average equity -76.90% -59.32%
Employees 56 -
CDP Score - -

Address

11400 Tomahawk Creek Pkwy Ste 340
LEAWOOD, KS 66211-2730
United States - Map
+1-913-3531000 (Phone)
+1-913-9049641 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aratana Therapeutics, Inc. is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company's portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. Its lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). AT-001 is a selective antagonist of the prostaglandin E2 (PGE 2) EP4 receptor (EP4 prostaglandin receptor antagonist or EP4 PRA). AT-002 is a potent and selective ghrelin agonist. Its product candidates also include AT-014, AT-016 and AT-018 for dogs.

Officers and directors

Wendy L. Yarno Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Steven St. Peter M.D. President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Craig A. Tooman Chief Financial Officer, Treasurer
Age: 49
Bio & Compensation  - Reuters
Brent Standridge Chief Operating Officer
Age: 58
Bio & Compensation  - Reuters
Ernst Heinen Ph.D. Chief Development Officer
Age: 52
Bio & Compensation  - Reuters
Julia A. Stephanus Chief Commercial Officer
Age: 56
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 58
Bio & Compensation  - Reuters
David L. Brinkley Independent Director
Age: 57
Bio & Compensation  - Reuters
Robert Benthall Gerber Jr. Independent Director
Age: 52
Bio & Compensation  - Reuters
Irvine O. Hockaday Esq. Independent Director
Age: 79
Bio & Compensation  - Reuters